Biopharma and medtech capital markets entered 2026 with selective momentum. In biopharma, licensing and M&A remained strong, helping lead venture and IPO activity. In medtech, improving exit conditions were supported by continued M&A activity and a modest reopening of the IPO market. Biopharma M&A totaled $15.6 billion across 19 deals, and six biopharma IPOs raised $1.8 billion—already surpassing full-year 2025 proceeds. Medtech M&A totaled $26.6 billion across 37 deals, while IPO activity remained selective, with one IPO raising $600 million on Nasdaq.
Read the full article: Biopharma and Medtech Activity in Q1 2026 //
Source: https://www.jpmorgan.com/insights/markets-and-economy/outlook/biopharma-medtech-deal-reports